Yeda Research and Develpment & Co. Ltd

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Hadassah Medical Organization

Hadassa Medical Organization

Amiram Eldor

Irun R Cohen

Yaakov Naparstek

Israel Vlodavsky

Miriam Kidron

Meir Rigbi

Ehud Ziv

Miriam Orevi

Hanoch Bar-On

A composition of matter useful as an inhibitor of blood platelet aggregation, for the treatment of various clinical disorders such as thrombotic, inflammatory and immunological disorders. This composition of matter is derived from the saliva of leeches of the Hirudinidae family. The composition contains various components, all having molecular weights lower than 2,000 daltons. The composition has an inhibitory activity against platelet aggregation induced by various aggregating agents, including Platelet Activating Factor-acether (PAF-acether), arachidonic acid, thrombin, ADP and epinephrine.

Platelet-aggregating inhibitory agents from leech saliva and

Heparanase activity in a patient may be inhibited by administering an effective heparanase-inhibiting amount of heparin or an effective chemically modified derivative of heparin which inhibits heparanase activity. Such derivatives are preferably N-desulfated, N-acetylated heparin or O-desulfated, N-acetylated heparin. By means of this invention, allograft rejection may be prevented or delayed and autoimmune diseases such as arthritis may be alleviated and treated.

Method for inhibiting heparanase activity

The invention relates to pharmaceutical compositions intended to decrease the incidence of tumor metastasis in patients who suffer from malignant diseases. The pharmaceutical compositions of the invention contain as active ingredient heparin or a suitable derivative thereof. Amongst suitable derivatives are N-desulfated and N-acetylated heparin. The dosage of the administered heparin or heparin derivative is quite critical and will generally be in the range of from 0.05 mg/kg/day to about 0.5 mg/kg/day. A preferred range is between about 0.1 mg/kg/day to about 0.5 mg/kg/day.

Method for decreasing tumor metastasis

The invention provides a pharmaceutical composition for the oral administration of insulin comprising insulin, a bile acid or alkali metal salt thereof, the bile acid being selected from the group consisting of cholic acid, chenodeoxycholic acid, taurocholic acid, taurochenodeoxycholic acid, glycocholic acid, glycochenocholic acid, 3.beta.-hydroxy-12-ketocholic acid, 12.alpha.-3.beta.-dihydrocholic acid, and ursodesoxycholic acid, and a protease inhibitor, the composition being provided with an enterocoating to assure passage through the stomach and release in the intestine.

Pharmaceutical compositions containing insulin

Growing community of inventors

Jerusalem, Israel

Amiram Eldor